Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: A Gynecologic Oncology Group study

Charles Kunos, Shamshad Ali, Fadi W. Abdul-Karim, Frederick B. Stehman, Steven Waggoner

Research output: Contribution to journalArticle

7 Scopus citations


Objective: The objective of the study was to study posttherapy chemoradiation hysterectomy histology with long-term survival in bulky stage 1B cervical cancer patients. Study Design: Gynecologic Oncology Group protocols 71 and 123 enrolled 464 patients randomly allocated to pelvic radiation (75 Gy, n = 291) plus hysterectomy (RTH) or to pelvic radiation (75 Gy) and cisplatin (40 mg/m2, n = 176) plus hysterectomy (RTCH). Risk of progression and death were evaluated by posttherapy hysterectomy response (good: <10% viable; poor: ≥10% viable). Results: Median survivor follow-up was 112 months. Relative risks of disease progression and death were 0.656 (95% confidence interval, 0.4720.912) and 0.638 (95% confidence interval, 0.449-0.908), favoring RTCH. Good response patients (345; 74%) had similar 10 year overall survival (OS) and progression-free survival (PFS) after RTH or RTCH (P > .47). Poor response patients after RTCH had superior OS (P = .046) and PFS (P = .084). Extrapelvic recurrences occurred more often in poor response patients. Conclusion: Posttherapy viable residual disease less than 10% was associated with reduced risk of progression and cancer-related death.

Original languageEnglish (US)
Pages (from-to)351.e1-351.e8
JournalAmerican Journal of Obstetrics and Gynecology
Issue number4
StatePublished - Oct 2010



  • cervix cancer
  • chemoradiation
  • hysterectomy histopathology

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Medicine(all)

Cite this